"Dyskinesia, Drug-Induced" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Descriptor ID |
D004409
|
| MeSH Number(s) |
C10.228.662.262.500 C10.597.350.275 C10.720.312 C23.888.592.350.275 C25.100.750 C25.723.705.200
|
| Concept/Terms |
Dyskinesia, Drug-Induced- Dyskinesia, Drug-Induced
- Drug-Induced Dyskinesia
- Drug-Induced Dyskinesias
- Dyskinesia, Drug Induced
- Dyskinesias, Drug-Induced
Dyskinesia, Medication-Induced- Dyskinesia, Medication-Induced
- Dyskinesia, Medication Induced
- Dyskinesias, Medication-Induced
- Medication-Induced Dyskinesias
- Medication-Induced Dyskinesia
- Medication Induced Dyskinesia
|
Below are MeSH descriptors whose meaning is more general than "Dyskinesia, Drug-Induced".
Below are MeSH descriptors whose meaning is more specific than "Dyskinesia, Drug-Induced".
This graph shows the total number of publications written about "Dyskinesia, Drug-Induced" by people in this website by year, and whether "Dyskinesia, Drug-Induced" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dyskinesia, Drug-Induced" by people in Profiles.
-
Castello J, Cort?s M, Malave L, Kottmann A, Sibley DR, Friedman E, Rebholz H. The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia. Sci Rep. 2020 02 13; 10(1):2542.
-
Young AS, Niv N, Cohen AN, Kessler C, McNagny K. The appropriateness of routine medication treatment for schizophrenia. Schizophr Bull. 2010 Jul; 36(4):732-9.
-
Chaudhuri A, Bowling K, Funderburk C, Lawal H, Inamdar A, Wang Z, O'Donnell JM. Interaction of genetic and environmental factors in a Drosophila parkinsonism model. J Neurosci. 2007 Mar 07; 27(10):2457-67.
-
Ozdemir V, Aklillu E, Mee S, Bertilsson L, Albers LJ, Graham JE, Caligiuri M, Lohr JB, Reist C. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother. 2006 Feb; 7(2):119-33.
-
Lamango NS, Ayuk-Takem LT, Nesby R, Zhao WQ, Charlton CG. Inhibition mechanism of S-adenosylmethionine-induced movement deficits by prenylcysteine analogs. Pharmacol Biochem Behav. 2003 Dec; 76(3-4):433-42.
-
Lutfy K, Weber E. Tolerance develops to the antinociceptive and motor impairing effects of ACEA-1416, a NMDA receptor antagonist, in the formalin and rotarod test in mice. Pharmacol Res. 1998 Apr; 37(4):295-302.
-
Suzuki T, Kurita H, Hori T, Sasaki M, Baba A, Shiraishi H, Piletz JE. The Pisa syndrome (pleurothotonus) during antidepressant therapy. Biol Psychiatry. 1997 Jan 15; 41(2):234-6.